290 patents
Page 14 of 15
Utility
Udp Glycosyltransferase Inhibitors and Methods of Use
1 Apr 20
Sungtaek LIM, Robert H. BARKER, JR., Mary A. CROMWELL, Elina MAKINO, Bradford HIRTH, John JIANG, Sachin MANIAR, Mark MUNSON, Yong-Mi CHOI, Sukanthini THURAIRATNAM, Kwon Yon MUSICK, James PRIBISH, Michael ANGELASTRO
Filed: 30 Sep 19
Utility
Polynucleotide Agents Targeting SERPINC1 (AT3) and Methods of Use Thereof
1 Apr 20
The invention relates to polynucleotide agents targeting the Serpinc1 (AT3) gene, and methods of using such polynucleotide agents to inhibit expression of Serpinc1 and to treat subjects having a bleeding disorder, e.g., a hemophilia.
Gregory Hinkle
Filed: 12 May 19
Utility
Method of preparing glucosylceramide synthase inhibitors
30 Mar 20
The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
Craig S. Siegel, Rayomand Gimi, Michael Reardon, Jin Zhao
Filed: 31 Jul 18
Utility
Microcarrier Perfusion Culturing Methods and Uses Thereof
11 Mar 20
Provided herein are methods of culturing a mammalian cell and various methods that utilize these culturing methods.
Jianguo Yang, Yang Yang
Filed: 27 Aug 19
Utility
Gene Therapy for Niemann-pick Disease Type a
11 Mar 20
This disclosure pertains to methods and compositions for tolerizing a mammal's brain to exogenously administered acid sphingomyelinase polypeptide by first delivering an effective amount of a transgene encoding the polypeptide to the mammal's hepatic tissue and then administering an effective amount of the transgene to the mammal's central nervous system (CNS).
Marco A. PASSINI, Robin J. ZIEGLER, James C. DODGE, Lamya SHIHABUDDIN, Seng H. CHENG
Filed: 18 Aug 19
Utility
Multi-dose compositions containing an antimicrobial polyamide or octenidine preservative
9 Mar 20
The present invention relates to non-mercurial preservatives, including antimicrobial polyamide polymers and octenidine, and to methods of use thereof to produce preservative-containing multi-dose formulations.
Guillaume Rigaut, Celine Loss-Dunod, Alexis Guy Andre Lucien Parisot, Pradeep K. Dhal
Filed: 12 Apr 17
Utility
Sterile Chromatography Resin and Use Thereof In Manufacturing Processes
4 Mar 20
Provided herein are methods of reducing bioburden of a chromatography resin that include exposing a container including a composition including (i) a chromatography resin and (ii) a liquid including at least on alcohol to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, where the at least one alcohol are present in an amount sufficient to ameliorate the loss of binding capacity of the chromatography resin after/upon exposure to the dose of gamma-irradiation.
Rohan Patil, Chad Varner
Filed: 15 Aug 19
Utility
Methods of perfusion culturing using a shake flask and microcarriers
2 Mar 20
Provided herein are methods of perfusion culturing an adherent mammalian cell using a shake flask and a plurality of microcarriers, and various methods that utilize these culturing methods.
Jianguo Yang, Yang Yang, Jennifer Tengtrakool, Weichang Zhou
Filed: 17 Jan 18
Utility
Seed train processes and uses thereof
24 Feb 20
Provided herein are seed train processes and methods of producing a recombinant protein that include the use of these seed train processes.
Michael Bruninghaus, Konstantin Konstantinov, Benjamin Wright, Weichang Zhou
Filed: 7 Jun 15
Utility
Gene Therapy for Retinitis Pigmentosa
12 Feb 20
Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708.
Catherine O'RIORDAN, Matthew ADAMOWICZ
Filed: 2 Jul 19
Utility
Glucosylceramide Synthase Inhibitors
12 Feb 20
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
Elyse BOURQUE, Mario CABRERA-SALAZAR, Cassandra CELATKA, Seng CHENG, Mary A. CROMWELL, Andrew GOOD, Bradford HIRTH, Katherine JANCSICS, John P. LEONARD, Lingyun LI, James LILLIE, Hanlan LIU, Elina MAKINO, John MARSHALL, Paul MASON, Markus METZ, Fazeela MORSHED, Thomas O'SHEA, Ronald SCHEULE, Renato SKERLJ, Bing WANG, Yibin XIANG, Zhong ZHAO
Filed: 14 Aug 19
Utility
Anti-Human CD52 Immunoglobulins
5 Feb 20
The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52.
Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
Filed: 9 Apr 19
Utility
Early Post-transfection Isolation of Cells (Epic) for Biologics Production
15 Jan 20
Provided herein are methods for selecting a population of cells expressing a target polypeptide.
Victor R. Cairns, Christine DeMaria, Jason Vitko
Filed: 22 Apr 19
Utility
Oligosaccharides Comprising an Aminooxy Group and Conjugates Thereof
8 Jan 20
The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group.
Yunxiang ZHU, Seng H. CHENG, Canwen JIANG, Luis Z. AVILA
Filed: 5 Feb 19
Utility
Chemokine Receptor Binding Heterocyclic Compounds with Enhanced Efficacy
1 Jan 20
The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings.
Gary J. Bridger, Renato T. Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason B. Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
Filed: 9 Apr 19
Utility
Methods for Treating Osteogenesis Imperfecta
25 Dec 19
The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ).
Brendan Lee, Kuber T. Sampath
Filed: 30 Jun 19
Utility
Multiple Oligonucleotide Moieties on Peptide Carrier
25 Dec 19
The present disclosure relates to antisense oligonucleotides (AONs), such as phosphorodiamidate morpholino oligonucleotides (PMOs).
Timothy E. WEEDEN, Carol A. NELSON, Bruce M. WENTWORTH, Nicholas P. CLAYTON, Andrew LEGER
Filed: 31 Jan 19
Utility
Combination therapy for treating breast cancer
16 Dec 19
The invention provides compositions and methods for treating breast cancer.
Jay Harper, Scott Lonning, Frank Hsu
Filed: 8 Jan 17
Utility
ScFv-Fc dimers that bind transforming growth factor-BETA1 with high affinity, avidity and specificity
16 Dec 19
An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity.
Huawei Qiu, Clark Pan, Julie Bird
Filed: 2 Mar 16
Utility
Hyperglycosylated binding polypeptides
2 Dec 19
Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering.
Clark Pan, Huawei Qiu, Pradeep Dhal, Bo Chen, Diego Gianolio
Filed: 4 Jun 17